Sign In
Buy AKTX
$14.99
+0.355 (+2.43%)
At Close: Jun 03, 2026
New cash portion of offering includes >20% participation from Directors, Officers and Executive Management New cash portion of offering includes >20% participation from Directors, Officers and Executi
Data highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest su
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
09:00am, Thursday, 04'th Dec 2025
Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for ant
Akari Therapeutics Announces Release of the Next CEO Corner Segment
09:00am, Tuesday, 25'th Nov 2025
Access the Akari CEO Corner here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody
Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript
07:08pm, Tuesday, 18'th Nov 2025
Akari Therapeutics, Plc ( AKTX ) Shareholder/Analyst Call November 18, 2025 11:00 AM EST Company Participants Abizer Gaslightwala - CEO, President & Director Satyajit Mitra - Executive Director & Head
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
08:35am, Tuesday, 18'th Nov 2025
More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track record scaling companies from precl
Data presented at the 40 th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activ
Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
09:25am, Tuesday, 04'th Nov 2025
Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9th Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Me
Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Up 66.7% in October
04:22am, Saturday, 01'st Nov 2025
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 248,0
Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phases Dr. Hurvitz is an international exper
Akari Therapeutics Announces Launch of CEO Corner Platform
09:05am, Wednesday, 22'nd Oct 2025
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for fut
Akari Therapeutics Announces $2.5 Million Registered Direct Offering
08:30am, Wednesday, 15'th Oct 2025
BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (AD
BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced
BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced
Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
08:45am, Wednesday, 24'th Sep 2025
Data highlights ability of Akari's ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression
